NAD<sup>+</sup>-Consuming Enzymes in Stem Cell Homeostasis

Ji, Xiuna; Zheng, Mingyue; Yu, Tao; Kang, Jie; Fan, Tingjun; Xu, Bin

doi:https://doi.org/10.1155/2023/4985726

Oxidative Medicine and Cellular Longevity

On this page

Abstract Introduction Conclusion Abbreviations Data Availability Conflicts of Interest Acknowledgments Supplementary Materials References Copyright Related Articles

Review Article | Open Access

Volume 2023 | Article ID 4985726 | https://doi.org/10.1155/2023/4985726

NAD⁺-Consuming Enzymes in Stem Cell Homeostasis

Xiuna Ji,¹Mingyue Zheng,²Tao Yu,³Jie Kang,¹Tingjun Fan,¹and Bin Xu¹

Academic Editor: Ivanov Alexander

Received11 Oct 2022

Revised27 Dec 2022

Accepted06 Jan 2023

Published08 Feb 2023

Abstract

Nicotinamide adenine dinucleotide (NAD⁺) is a coenzyme used in redox reactions, energy metabolism, and mitochondrial biogenesis. NAD⁺ is also required as a cofactor by nonredox NAD⁺-dependent enzymes. Hundreds of enzymes that consume NAD⁺ have been identified. The NAD⁺-consuming enzymes are involved in a variety of cellular processes such as signal transduction, DNA repair, cellular senescence, and stem cell (SC) homeostasis. In this review, we discussed how different types of NAD⁺-consuming enzymes regulate SC functions and summarized current research on the roles of the NAD⁺ consumers in SC homeostasis. We hope to provide a more global and integrative insight to the mechanism and intervention of SC homeostasis via the regulation of the NAD⁺-consuming enzymes.

1. Introduction

Nicotinamide adenine dinucleotide (NAD⁺) has been described as central coenzyme for redox reactions [1]. During the oxidation of glucose and fatty acids, NAD⁺ is reduced to NADH, which acts as a ubiquitous cellular electron donor. Two NADH are generated by glycolysis and converted back to NAD⁺ [2]. In addition to energy metabolism, NAD⁺ is used as a cofactor or cosubstrate by hundreds of enzymes [3]. This net consumption of NAD⁺ is compensated by de novo starting with tryptophan, or from salvage pathways starting with NAD⁺ precursors, thus maintaining a balanced pool under normal physiological conditions [2].

The diverse enzymes consuming NAD⁺ are found in almost all eukaryotic cells (Figure 1). They have multiple roles in the regulation of cellular processes and functions such as DNA repair, epigenetic modification, and inflammation [4]. These enzymes can be divided into two categories involved in a variety of cellular processes, including stress response, mitochondrial homeostasis, and calcium signaling [5]. The first category breaks down NAD⁺ and transfers the adenosine diphosphate- (ADP-) ribose units to fundamental biomolecules. The second hydrolyzes NAD⁺ to ADP-ribose (ADPR), cyclic ADPR (cADPR), and nicotinamide (NAM), which are dominated by multifunctional ectoenzymes with both glycohydrolase and ADP-ribosyl cyclase activities (Figure 2) [6, 7]. Recent reports show that the above NAD⁺ consumers attracted more attentions in the field of stem cell (SC) homeostasis mechanism and intervention [8]. Therefore, in this review, we focus on the current advances in the roles of NAD⁺-consuming enzymes in SC homeostasis.

Figure 1

Locations of NAD⁺-consuming enzymes. SIRT1 is reported to locate in both in nucleus and cytosol. SIRT2, predominantly resided in cytosol, may also exist in mitochondria and nucleus. SIRT3 is a major mitochondrial deacetylase and also plays a role in nucleus. SIRT4 is only found in mitochondria. SIRT5 locates in mitochondrial matrix and intermembrane space, cytosol, peroxisome, and nucleus. SIRT6 is only found in nucleus. SIRT7 is the only sirtuin protein that mainly locates in nucleolus. PARPs reside in cytosol, mitochondria, and nucleus. CD38 is observed both in plasma membrane (catalytic domain facing outside or inside) and intracellular membranes (including endoplasmic reticulum, nucleus, mitochondria, and endolysosome). CD157 is a glycophosphatidylinositol-anchored protein with the catalytic domain facing outside. Sterile alpha and Toll/interleukin receptor (TIR) motif-containing 1 (SARM1) locates in cytosol, mitochondria, and nucleus. Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) is found in mitochondria and nucleus. NAD⁺ kinase (NADK) only resides in cytosol.

Figure 2

Catalytic reactions of NAD⁺-consuming enzymes using NAD⁺ as a substrate. Sirtuins remove acyl groups from lysine residues on target substrates including proteins and lipids. ADP-ribose (ADPR) cleaved from NAD⁺ serves as an acyl group acceptor to generate acetyl-ADPR. PARPs transfer the ADP-ribose from NAD⁺ to proteins, DNA, and RNA (known as PARylation). CD38, CD157, and sterile alpha and Toll/interleukin receptor (TIR) motif-containing 1 (SARM1) are multifunctional ectoenzymes with both glycohydrolase and ADP-ribosyl cyclase activities. Their main catalytic activity is the hydrolysis of NAD⁺ to NAM and ADP-ribose (ADPR). They also catalyze NAD⁺ to NAM and cADPR. Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) uses NAD⁺ to generate NADH. NAD⁺ can also be consumed by NAD⁺ kinase (NADK) to increase NADP⁺ production. Then NADP⁺ is catalyzed to NAADP by CD38.

The literature search produced a total of 49,519 records (39,570 from Web of Science and 9,949 from PubMed). After title/abstract/language/literature evaluation screening, 99 articles were assessed for full-text eligibility, an additional 22 studies identified through review articles, and a final total of 121 articles were included in the final review (Figure S1).

2. Category I: Deacylases (Sirtuins (SIRTs) and Poly(ADP-Ribose) Polymerases (PARPs))

2.1. Sirtuins

There are seven sirtuins (SIRT1–7) with a conserved NAD⁺-binding domain in mammals [9, 10]. Sirtuins have various activities, containing different lysine deacetylation reactions, ADP ribosylation, and removal of lipid modifications [11, 12]. They have been found to play roles in multiple cellular functions, such as genomic stability, transcription, signal transduction, and metabolism [13]. Recent studies report that they also directly or indirectly participate in the regulation of multiple signaling pathways to maintain SC homeostasis (Table 1).

2.1.1. SIRT1 (Metabolome-Epigenome Crosstalker)

SIRT1, located both in the nucleus and cytosol, is the largest one in molecular mass and the most extensively studied sirtuin protein [14]. It has been reported to play a crucial role in the SC self-renewal. SIRT1 does not only mediate mouse embryonic SC (mESC) maintenance and embryonic development through deacetylation of methionine adenosyltransferase 2a (MAT2a) [15] but, also modulate mESC differentiation via c-Myc-SMPDL3B signaling cascades [16].

There is growing evidence that decreasing intracellular NAD⁺ level and SIRT1 activity are associated with SC senescence in vivo. The reduction of cellular NAD⁺ pools blunts the adaptive mitochondrial unfolded protein response (UPR^mt) pathway, ultimately leading to a loss of mitochondrial homeostasis in a SIRT1-dependent manner. Mitochondrial dysfunction is a biomarker of muscle SC (MuSC) senescence that reduces SC cell number and self-renewal capacity [8]. Moreover, cell culture expansion in vitro induces replicative senescence and loss of NAD⁺ homeostasis in hMSCs which correlates with the decreasing of the SIRT1 signaling activity [17]. Similarly, nicotinamide phosphoribosyltransferase (NAMPT), known as a rate-limiting enzyme in the NAD⁺ salvage pathway, suppresses rat MSC senescence via NAD⁺-SIRT1 signaling [18]. Above results demonstrate that NAD⁺-SIRT1 axis dysfunction might be a potential checkpoint for stemness loss and homeostasis disruption of SCs.

Furthermore, the NAD⁺-dependent SIRT1 switches metabolic signaling into epigenetics regulation by decreasing H4K16 acetylation and inactivation of muscle gene transcription in MuSCs [14]. SIRT1 also regulates neural SC (NSC) fates by modulating the circadian clock possibly through FOXO3a deacetylation and acts as a gatekeeper of NSCs by responding to metabolic stress [19]. Similarly, SIRT1 also plays an important role in the maintenance of cancer stem cell (CSC) self-renewal. SIRT1 deacetylates β-catenin to trigger its concentration in the nucleus. The nuclear β-catenin further promotes the transcription of NANOG, which aids in the maintenance of liver CSC self-renewal [20]. SOX2 is also a key downstream regulator of SIRT1-mediated liver CSC self-renewal and tumorigenicity. SIRT1 controls the SOX2 gene transcription through chromatin-based epigenetic modification that is reliant on DNA methylation [21]. These results imply its important regulatory roles in the metabolome-epigenome signaling cascade in SC homeostasis.

2.1.2. SIRT2 (Major Cytosolic Sirtuin)

SIRT2 is the only sirtuin protein predominantly resided in the cytosol, although it has also been found in the mitochondria and nucleus [22, 23]. It is identified as a direct regulator of PAX7 acetylation and asymmetric division in MuSCs [24]. SIRT2 also prevents mitochondrial stress-induced hematopoietic SC (HSC) death by repressing NLRP3 inflammasome and caspase 1 activation [25]. In addition, SIRT2 inhibits the activities of four glycolytic enzymes (ALDOA, GAPDH, PGK1, and ENO1) by regulating their acetylation status, thereby interfering the metabolic state during somatic reprogramming of induced pluripotent SCs (iPSCs) [26]. These findings suggest that SIRT2 might be another key enzyme in SC homeostasis, involved in transcriptional activity, inflammatory response, and metabolic switch.

2.1.3. SIRT3 (Dual Function for Mitochondrial Homeostasis and Genomic Stability)

SIRT3 is a major mitochondrial deacetylase, regulating mitochondrial metabolism [27], also reported to have a role in deacetylating histones in the nucleus [28]. It is the most abundant sirtuin family member in HSCs for their homeostasis [29]. SIRT3 cooperates with autophagy by promoting its expression to decelerate hematopoietic aging, and positive intervention to the autophagy-SIRT3 axis leads to blood rejuvenation [30]. Besides, SIRT3 decreases in human MSCs with in vitro passaging; its knockdown accelerates aging and inhibits efficient differentiation of MSCs into adipocytes and osteoblasts; instead, SIRT3 overexpression restores their differentiation capacity and reduces oxidative stress in later-passage MSCs [31]. The mechanisms involved may contribute to that SIRT3 helps to activate antioxidant enzymes (i.e., CAT and MnSOD) [32] and mitophagy inducing by enhanced mitochondrial ROS [33] and stabilize heterochromatin to counteract MSC senescence by interacting with nuclear envelope proteins and heterochromatin-associated proteins [34]. SIRT3 is also related to regulating mitochondrial quality and function for cellular adaption to hypoxia in rat MSCs [35], promoting β cell maturation of mouse ES cells through tricarboxylic acid cycle [36], and ameliorating microglia activation-induced oxidative stress injury through mitochondrial apoptosis pathway in mouse NSCs [37]. A recent research has found that aerobic respiration is upregulated in spermatogonial stem cell (SSC) differentiation in a SIRT3-dependent manner [38, 39]. Above reports show that SIRT3 might regulate SC behavior through multiple pathways, including mitochondrial homeostasis and genomic stability.

2.1.4. SIRT4 (Negative Regulatory Switch)

SIRT4 plays a critical role in cellular metabolism and DNA damage responses in mitochondria [40]. Compared with the other mitochondrial sirtuins, the enzymatic activity of SIRT4 is poorly understood in SCs [12]. Its overexpression triggers senescence in trophoblast SCs (TSCs) due to redox imbalance [41]. Loss of SIRT4 promotes the self-renewal of breast CSCs [42]. SIRT4 appears to exhibit a negative regulatory effect on SC homeostasis, while it remains fundamentally unexplored.

2.1.5. SIRT5 (the Most Widely Functional Sirtuin?)

SIRT5 is a mitochondrial sirtuin localized to the mitochondrial matrix [43]. Interestingly, its target proteins have been found in the mitochondrial matrix and intermembrane space [44], cytosol [45], peroxisome [46], and nucleus [47]. Successive passages in vitro cause SIRT5 accumulation in adipose-derived mesenchymal SCs (ADMSCs) with loss of stemness, eventually accelerating cell senescence. SIRT5-deficient ADMSCs exhibit a higher proliferation rate, delayed senescence, decreasing ROS accumulation, and elevating aerobic glycolysis and attenuating mitochondrial respiration in a more endogenous metabolic pattern [48]. In contrast, SIRT5 has also been reported to have positive effects on oxidative phosphorylation [49, 50]. Considering oxidative phosphorylation as the major source of ROS, it is quite surprising that SIRT5-deficient murine embryonic fibroblasts (MEFs) show higher ROS levels [50]. Although SIRT5 function is not well defined, it may be a potential target to promote the self-renewal capacities and maintain the physiological functions of SCs due to its multiple cellular locations [51].

2.1.6. SIRT6 (Specific Switch of Histone H3)

SIRT6, only found in the nucleus, specifically modifies histone H3 to regulate several fundamental processes about lifespan [52]. SIRT6-deficient HSCs exhibited impaired self-renewal ability [53], and its roles in maintaining SC homeostasis and human development might be related to modification of histone H3. Besides, its chromatin remodeling activity is a critical modulator of human development, regulating the transition from pluripotency to differentiated state [54–57]. Human iPSCs derived from SIRT6 Asp63His (D63H) mutant fail to differentiate into embryoid bodies (EBs), functional cardiomyocytes, and neural progenitor cells (NPCs) because of sustained pluripotent gene expression [54]. However, it has been reported to maintain MSC homeostasis by serving as a NRF2 coactivator to transactivate the NRF2-driven antioxidant genes [58]. SIRT6 can also regulate HSC homeostasis through the transcriptional repression of Wnt target genes. Therefore, the function of SIRT6 in maintaining SC homeostasis may not be limited to the nucleus.

2.1.7. SIRT7 (Specific Nucleolar Sirtuin)

SIRT7 is the only sirtuin protein that mainly localizes to the nucleolus [59], involving in ribosomal biogenesis [60], stress responses [61], and senescence [62]. In HSCs, SIRT7 interacts NRF1 to regulate cellular energy metabolism and proliferation through the UPR^mt. In addition, SIRT7 upregulation improved the regenerative capacity of aged HSCs [63] and hMSCs [64]. Mechanistically, SIRT7 forms a complex with nuclear lamins and heterochromatin proteins to maintain the repressive state of heterochromatin [64]. It also can activate quiescent hair follicle SCs (HFSCs) to initiate the cell cycle by destabilizing NFATc1 [65] and regulate MSC osteogenic differentiation partly by activating Wnt/β-catenin signaling [66]. Because of its special location, SIRT7 may play a special role in the regulation of SC homeostasis, which is worthy of further study.

Some sirtuins are detected in multiple cellular compartments, and to shuttle among the various cellular localizations [67]. Different sirtuins have complementary functions and extensive crosstalk to maintain SC homeostasis, besides their own distinct functions. For instance, mitochondrial sirtuins are able to manage these delicate processes accurately by crosstalk between the mitochondria and nucleus [12]. Yuan et al. reported that the reducing expressions of SIRT1 and SIRT3 fail to regulate mitochondrial fitness, DNA repair, and other aging-associated pathways during hMSC culture expansion [17]. SIRT4 and SIRT1 have an inverse relationship in breast CSCs, and SIRT4 inhibits SIRT1 expression by suppressing glutamine metabolism [42]. However, their cooperative relationship and mechanisms are still unclear and poorly understood, and more in-depth studies are needed [12].

2.2. PARPs

PARPs family consisted of 17 proteins, widely distributed in all human tissues, and involved in a variety of cellular functions, such as the cellular response to DNA damage and the regulation of gene transcription [68, 69]. PARPs transfer the ADP-ribose from NAD⁺ to fundamental biomolecules (known as PARylation) containing proteins, DNA, and RNA [11, 70–73]. Recently, PARP research has been enriched by the discovery of novel PARP1 interaction partners that regulate its enzymatic activity [74, 75]. It shows that PARP1 contributes to pluripotency, lineage specific differentiation, and reprogramming in various SCs [76].

PARP1 is a component of the groucho/TLE-corepressor complex, which mediates dismissal of the corepressor complex from HES1-regulated promoters during neural stem/progenitor cell (NSC) differentiation [77]. During this process, PARP1 mediates histone H1 eviction from the chromatin fiber [78]. Similarly, PARP1 interacts with PARylates SOX2 directly, in which it may be required for dissociation and degradation of inhibitory SOX2 proteins from the FGF4 enhancer during ESC differentiation [79]. PARP1 can also dominate NSC proliferation by modulating platelet-derived growth factor receptor α (PDGFRα) expression [80]. PARylation is reported to promote the proliferation and self-renewal of mouse brain NSCs by inhibiting p53 activation [81]. PARP1 loss leads to defects in brain development, increased neuronal density at birth in mice, and enhanced embryonic NSC adhesion to N-cadherin in vitro [82].

These results demonstrate the chromatin-related function of PARP1, which PARylates different transcription factors to modulate their DNA binding and transcriptional activity, thereby regulating SC homeostasis [83]. Therefore, site-specific PARylation to drive cell fate may be a very promising approach in SC therapy. Remarkably, CSCs have an increased DNA damage response, and PARP1 is upregulated due to its crucial involvement in DNA repair [84, 85]. It implies that PARP inhibitors can be employed as therapeutic strategies to target CSCs, such as FDA-approved olaparib and rucaparib.

3. Category II: NAD⁺ Glycohydrolases (Also Referred to as NADases, including CD38, CD157, and Sterile Alpha and Toll/Interleukin Receptor (TIR) Motif-Containing 1 (SARM1))

3.1. CD38

CD38 is considered a type II protein with the catalytic domain facing outside. It can also exist in an opposite type III orientation with its catalytic domain facing the cytosol [63, 86]. CD38 is observed in intracellular membranes, including endoplasmic reticulum, nucleus, mitochondria, and endolysosome [63, 87–90]. It catalyzes the synthesis of ADPR and cADPR using NAD⁺ as a substrate and is an important regulator of extracellular and intracellular NAD⁺ pools [91]. Both ADPR and cADPR act as second messengers controlling multiple cell functions through inducing intracellular Ca²⁺ fluxes independent of IP3 [92]. CD38 has been reported to play a role in SC differentiation [93]. For example, the NAD⁺/CD38/cADPR/Ca²⁺ signaling pathway antagonizes the cardiomyocyte differentiation of mouse ESCs [94].

Remarkably, increasing CD38 expression leads to a decline of NAD metabolites and distorts other NAD⁺-consuming enzyme activities in aged mice [91]. CD38 but not SIRT1 or PARPs is considered the predominant NAD⁺ consumers [95]. Therefore, it should also be considered whether CD38 has a specific regulatory role in SC senescence.

3.2. CD157

CD157 is a glycophosphatidylinositol-anchored protein. The ADP-ribosyl cyclase activity of CD157 is weaker than that of CD38. CD157 may participate in the embryonic and adult nervous systems partially through cADPR production [96]. CD157 upregulation increases the biosynthesis and transition of mitochondria from BMSCs to injured neurons, thus improves the neuroregeneration and inhibits cell apoptosis via calcium-dependent CD157/cyclic ADP-ribose pathway [97]. In addition, CD157 is a marker of tissue-resident vascular endothelial SCs (VESCs) [98, 99]. The CD157-positive endothelial cells have SC properties, including homeostatic capillary maintenance and regenerative capacity after vascular injury in vivo [100]. However, whether the functions of CD157 as a cell receptor are relevant to NAD⁺ metabolism remains unclear [3].

3.3. SARM1

The Toll/interleukin receptor (TIR) domain is necessary for SARM1 activity. Dimerization of TIR domain cleaves NAD⁺ into ADP-ribose, cADPR, and NAM [7, 101]. In addition to its involvement in innate immunity [102, 103], SARM1 is thought to an important NAD⁺-consuming enzyme during axonal injury in neurons [1, 104, 105]. Inhibition of SARM1 activation may be a compelling therapeutic target to treat neurodegenerative diseases [106–108]. However, the role of SARM1 in regulating SC homeostasis is currently unclear. Our RNA-Seq results (SRA: SRP152900) revealed significantly higher levels of SARM1 expression in differentiated limbal SCs (LSCs) compared to undifferentiated ones. This suggests that maintaining SC stemness may also require inhibition of SARM1 activation.

Moreover, one-carbon metabolism enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) has been reported to use NAD⁺ as a cofactor [109]. It is a dual-function factor for determining the pluripotency of pluripotent SCs through both preventing mitochondrial dysfunction and promoting homologous recombination repair in nucleus [110]. NAD⁺ can also be consumed by NAD⁺ kinase (NADK) to increase NADP⁺ production [111]. Through CD38, NADP⁺ is further converted into NAADP, which is another Ca²⁺-mobilizing second messenger [112]. Unfortunately, there is no report on crosstalk between NADK and CD38 in the regulation of SC homeostasis.

4. Conclusion

The NAD⁺ consumers systematically reduce the pool of NAD⁺ available for NAD⁺-specific enzymes and processes [11, 13]. These different enzymes can also interplay with each other to perform the same cellular function (Table 2). For instance, aging triggers NAD⁺ loss because of PARP activation in old mice, and NAD⁺ reduction lowers the activity of the antiaging proteins, sirtuins, leading to a feedforward cycle of aging [8, 113]. Another study found that CD38 has a central role in age-related NAD⁺ decline. CD38 inhibitor 78c upregulates NAD⁺ levels, thereby activating prolongevity and health span-related factors, including sirtuins and PARPs [114]. Moreover, PARP inhibitor PJ34 preserved intracellular NAD⁺ levels, increased SIRT1 activity, and improved the function in aging-induced endothelial progenitor cells (EPCs) [115]. In CSCs, NAMPT regulates epithelial-mesenchymal transition (EMT) and tumor dedifferentiation/reprograming via controlling cellular functions that promote proliferation and pathways mediated by SIRT1 and PARP1 [116]. Above results suggest that NAD⁺ availability can be achieved by inhibiting one or more of the NAD⁺ consumers to crosstalk the regulatory networks. Of course, SC functions might be restored or improved by supplying NAD⁺ precursors for biosynthesis [17, 50], including nicotinamide riboside (NR) [8, 117–119], NAM [120], and nicotinamide mononucleotide (NMN) (Table 3) [121]. This may be a potential approach for maintaining SC homeostasis and is a challenge for clinical treatment of related diseases.

Abbreviations

ADMSC:	Adipose-derived mesenchymal stem cell
ADP:	Adenosine diphosphate
ADPR:	ADP-ribose
ALDOA:	Aldolase A
cADPR:	Cyclic ADPR
CAT:	Catalase
CSC:	Cancer stem cells
EB:	Embryoid body
EPC:	Endothelial progenitor cell
EMT:	Epithelial-mesenchymal transition
ENO1:	Enolase 1
FGF4:	Fibroblast growth factor 4
FOXO3a:	Forkhead box O3a
GAPDH:	Glyceraldehyde-3-phosphate dehydrogenase
HFSC:	Hair follicle stem cell
HSC:	Hematopoietic stem cell
iPSC:	Induced pluripotent stem cell
LSC:	Limbal stem cell
MAT2a:	Methionine adenosyltransferase 2a
MEF:	Murine embryonic fibroblast
mESC:	Mouse embryonic stem cell
MTHFD2:	Methylenetetrahydrofolate dehydrogenase 2
MuSC:	Muscle stem cell
MnSOD:	Manganese superoxide dismutase
NAD⁺:	Nicotinamide adenine dinucleotide
NADK:	NAD⁺ kinase
NAM:	Nicotinamide
NAMPT:	Nicotinamide phosphoribosyltransferase
NFATc1:	Nuclear factor of activated T cells c1
NLRP3:	Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3
NPC:	Neural progenitor cell
NRF1:	Nuclear factor erythroid 2-related factor 1
NRF2:	Nuclear factor erythroid 2-related factor 2
NMN:	Nicotinamide mononucleotide
NR:	Nicotinamide riboside
NSC:	Neural stem cell
PARP:	Poly(ADP-ribose) polymerase
PAX7:	Paired box 7
PDGFRα:	Platelet-derived growth factor receptor α
PGK1:	Phosphoglycerate kinase 1
ROS:	Reactive oxygen species
SARM1:	Sterile alpha and Toll/interleukin receptor (TIR) motif-containing 1
SC:	Stem cell
SIRT:	Sirtuin
SMPDL3B:	Sphingomyelin phosphodiesterase acid-like 3B
SOX2:	SRY-box transcription factor 2
SSC:	Spermatogonial stem cell
TET2:	Ten-eleven translocation-2
TIR:	Toll/interleukin receptor
TSC:	Trophoblast stem cell
UPR^mt:	Mitochondrial unfolded protein response
VESC:	Vascular endothelial stem cell.

Data Availability

Our RNA-Seq data supporting this review have been deposited in the Sequence Read Archive (SRA) database at NCBI under the accession number SRP152900. The raw data are available (https://www.ncbi.nlm.nih.gov/sra/SRP152900).

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 31601104) and the Natural Science Foundation of Shandong Province (No. ZR2021MC158).

Supplementary Materials

Supplementary Figure S1: literature search method and selection criteria. Searches in Web of Science and PubMed were restricted to papers published between 2016 and 2022. The basic framework of the intervention program was determined by searching for a combination of subject terms and free words, such as “stem cell,” “NAD enzyme,” and “homeostasis.” Exclusion criteria for literature are as follows: no complete text accessible; publications written in a language other than English; and studies with inadequate literature evaluation. (Supplementary Materials)

References

E. Katsyuba, M. Romani, D. Hofer, and J. Auwerx, “NAD⁺ homeostasis in health and disease,” Nature Metabolism, vol. 2, no. 1, pp. 9–31, 2020.
View at: Publisher Site | Google Scholar
C. Tannous, G. W. Booz, R. Altara et al., “Nicotinamide adenine dinucleotide: biosynthesis, consumption and therapeutic role in cardiac diseases,” Acta Physiologica, vol. 231, no. 3, article e13551, 2021.
View at: Publisher Site | Google Scholar
A. J. Covarrubias, R. Perrone, A. Grozio, and E. Verdin, “NAD⁺ metabolism and its roles in cellular processes during ageing,” Nature Reviews. Molecular Cell Biology, vol. 22, no. 2, pp. 119–141, 2021.
View at: Publisher Site | Google Scholar
M. N. Navarro, M. M. G. de Las Heras, and M. Mittelbrunn, “Nicotinamide adenine dinucleotide metabolism in the immune response, autoimmunity and inflammageing,” British Journal of Pharmacology, vol. 179, no. 9, pp. 1839–1856, 2022.
View at: Publisher Site | Google Scholar
K. M. Ralto, E. P. Rhee, and S. M. Parikh, “NAD⁺ homeostasis in renal health and disease,” Nature Reviews Nephrology, vol. 16, no. 2, pp. 99–111, 2020.
View at: Publisher Site | Google Scholar
J. Shang, M. R. Smith, A. Anmangandla, and H. Lin, “NAD⁺-consuming enzymes in immune defense against viral infection,” The Biochemical Journal, vol. 478, no. 23, pp. 4071–4092, 2022.
View at: Google Scholar
N. Xie, L. Zhang, W. Gao, C. Huang, and B. Zou, “NAD⁺ metabolism: pathophysiologic mechanisms and therapeutic potential,” Signal Transduction and Targeted Therapy, vol. 5, no. 1, p. 227, 2020.
View at: Publisher Site | Google Scholar
H. Zhang, D. Ryu, Y. Wu et al., “NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice,” Science, vol. 352, no. 6292, pp. 1436–1443, 2016.
View at: Publisher Site | Google Scholar
J. Du, Y. Zhou, X. Su et al., “Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase,” Science, vol. 334, no. 6057, pp. 806–809, 2011.
View at: Publisher Site | Google Scholar
S. I. Imai, C. M. Armstrong, M. Kaeberlein, and L. Guarente, “Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase,” Nature, vol. 403, no. 6771, pp. 795–800, 2000.
View at: Publisher Site | Google Scholar
X. A. Cambronne and W. L. Kraus, “Location, Location, Location: Compartmentalization of NAD⁺ Synthesis and Functions in Mammalian Cells,” Trends in Biochemical Sciences, vol. 45, no. 10, pp. 858–873, 2020.
View at: Publisher Site | Google Scholar
M. S. Elkhwanky and J. Hakkola, “Extranuclear sirtuins and metabolic stress,” Antioxidants & Redox Signaling, vol. 28, no. 8, pp. 662–676, 2018.
View at: Publisher Site | Google Scholar
M. Wang and H. Lin, “Understanding the function of mammalian sirtuins and protein lysine acylation,” Annual Review of Biochemistry, vol. 90, no. 1, pp. 245–285, 2021.
View at: Publisher Site | Google Scholar
J. G. Ryall, S. Dell’Orso, A. Derfoul et al., “The NAD⁺-dependent SIRT1 deacetylase translates a metabolic switch into regulatory epigenetics in skeletal muscle stem cells,” Cell Stem Cell, vol. 16, no. 2, pp. 171–183, 2015.
View at: Publisher Site | Google Scholar
S. Tang, Y. Fang, G. Huang et al., “Methionine metabolism is essential for SIRT1-regulated mouse embryonic stem cell maintenance and embryonic development,” The EMBO Journal, vol. 36, no. 21, pp. 3175–3193, 2017.
View at: Publisher Site | Google Scholar
W. Fan, S. Tang, X. Fan et al., “SIRT1 regulates sphingolipid metabolism and neural differentiation of mouse embryonic stem cells through c-Myc-SMPDL3B,” eLife, vol. 10, article e67452, 2021.
View at: Publisher Site | Google Scholar
X. Yuan, Y. Liu, B. M. Bijonowski et al., “NAD⁺/NADH redox alterations reconfigure metabolism and rejuvenate senescent human mesenchymal stem cells in vitro,” Communications Biology, vol. 3, no. 1, p. 774, 2020.
View at: Publisher Site | Google Scholar
C. Pi, Y. Yang, Y. Sun et al., “Nicotinamide phosphoribosyltransferase postpones rat bone marrow mesenchymal stem cell senescence by mediating NAD⁺-Sirt1 signaling,” Aging, vol. 11, no. 11, pp. 3505–3522, 2019.
View at: Publisher Site | Google Scholar
S. Draijer, I. Chaves, and M. F. M. Hoekman, “The circadian clock in adult neural stem cell maintenance,” Progress in Neurobiology, vol. 173, pp. 41–53, 2019.
View at: Publisher Site | Google Scholar
X. Chen, H. Huan, C. Liu et al., “Deacetylation of β-catenin by SIRT1 regulates self-renewal and oncogenesis of liver cancer stem cells,” Cancer Letters, vol. 463, pp. 1–10, 2019.
View at: Publisher Site | Google Scholar
L. Liu, C. Liu, Q. Zhang et al., “SIRT1-mediated transcriptional regulation of SOX2 is important for self- renewal of liver cancer stem cells,” Hepatology, vol. 64, no. 3, pp. 814–827, 2016.
View at: Publisher Site | Google Scholar
A. Vaquero, M. B. Scher, D. H. Lee et al., “SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis,” Genes & Development, vol. 20, no. 10, pp. 1256–1261, 2006.
View at: Publisher Site | Google Scholar
G. Liu, S. H. Park, M. Imbesi et al., “Loss of NAD-dependent protein deacetylase sirtuin-2 alters mitochondrial protein acetylation and dysregulates mitophagy,” Antioxidants & Redox Signaling, vol. 26, no. 15, pp. 849–863, 2017.
View at: Publisher Site | Google Scholar
M. C. Sincennes, C. E. Brun, A. Y. T. Lin et al., “Acetylation of PAX7 controls muscle stem cell self-renewal and differentiation potential in mice,” Nature Communications, vol. 12, no. 1, p. 3253, 2021.
View at: Publisher Site | Google Scholar
H. Luo, W. C. Mu, R. Karki et al., “Mitochondrial stress-initiated aberrant activation of the NLRP3 inflammasome regulates the functional deterioration of hematopoietic stem cell aging,” Cell Reports, vol. 26, no. 4, pp. 945–954.e4, 2019.
View at: Publisher Site | Google Scholar
T. M. Liu and N. Shyh-Chang, “SIRT2 and glycolytic enzyme acetylation in pluripotent stem cells,” Nature Cell Biology, vol. 19, no. 5, pp. 412–414, 2017.
View at: Publisher Site | Google Scholar
T. Shimazu, M. D. Hirschey, L. Hua et al., “SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production,” Cell Metabolism, vol. 12, no. 6, pp. 654–661, 2010.
View at: Publisher Site | Google Scholar
M. B. Scher, A. Vaquero, and D. Reinberg, “SirT3 is a nuclear NAD(+)-dependent histone deacetylase that translocates to the mitochondria upon cellular stress,” Genes & Development, vol. 21, no. 8, pp. 920–928, 2007.
View at: Publisher Site | Google Scholar
K. Brown, S. Xie, X. Qiu et al., “SIRT3 reverses aging-associated degeneration,” Cell Reports, vol. 3, no. 2, pp. 319–327, 2013.
View at: Publisher Site | Google Scholar
Y. Fang, N. An, L. Zhu et al., “Autophagy-Sirt3 axis decelerates hematopoietic aging,” Aging Cell, vol. 19, no. 10, article e13232, 2020.
View at: Publisher Site | Google Scholar
R. A. Denu, “SIRT3 enhances mesenchymal stem cell longevity and differentiation,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 5841716, 11 pages, 2017.
View at: Publisher Site | Google Scholar
D. Y. Zhang, T. Gao, R. J. Xu et al., “SIRT3 transfection of aged human bone marrow-derived mesenchymal stem cells improves cell therapy-mediated myocardial repair,” Rejuvenation Research, vol. 23, no. 6, pp. 453–464, 2020.
View at: Publisher Site | Google Scholar
Y. Guo, X. Jia, Y. Cui, Y. Song, and D. Fu, “Sirt3-mediated mitophagy regulates AGEs-induced BMSCs senescence and senile osteoporosis,” Redox Biology, vol. 41, no. 1, article 101915, 2021.
View at: Publisher Site | Google Scholar
Z. Diao, Q. Ji, Z. Wu et al., “SIRT3 consolidates heterochromatin and counteracts senescence,” Nucleic Acids Research, vol. 49, no. 8, pp. 4203–4219, 2021.
View at: Publisher Site | Google Scholar
X. Wang, K. Shen, J. Wang et al., “Hypoxic preconditioning combined with curcumin promotes cell survival and mitochondrial quality of bone marrow mesenchymal stem cells, and accelerates cutaneous wound healing via PGC-1α/SIRT3/HIF-1α signaling,” Free Radical Biology & Medicine, vol. 159, pp. 164–176, 2020.
View at: Publisher Site | Google Scholar
L. Lu, L. Zhitao, C. Nannan et al., “Mitofusin2 promotes beta cell maturation from mouse embryonic stem cells via Sirt3/Idh2 activation,” Stem Cells International, vol. 2022, Article ID 1172795, 18 pages, 2022.
View at: Publisher Site | Google Scholar
D. Q. Jiang, Y. Wang, M. X. Li, Y. J. Ma, and Y. Wang, “SIRT3 in neural stem cells attenuates microglia activation-induced oxidative stress injury through mitochondrial pathway,” Frontiers in Cellular Neuroscience, vol. 11, p. 7, 2017.
View at: Publisher Site | Google Scholar
B. P. Hermann, K. Cheng, A. Singh et al., “The mammalian spermatogenesis single-cell transcriptome, from spermatogonial stem cells to spermatids,” Cell Reports, vol. 25, no. 6, pp. 1650–1667.e8, 2018.
View at: Publisher Site | Google Scholar
T. Lord and B. Nixon, “Metabolic changes accompanying spermatogonial stem cell differentiation,” Developmental Cell, vol. 52, no. 4, pp. 399–411, 2020.
View at: Publisher Site | Google Scholar
D. Van, D. Santos, and M. C. Haigis, “Mitochondrial sirtuins and molecular mechanisms of aging,” Trends in Molecular Medicine, vol. 23, no. 4, pp. 320–331, 2017.
View at: Publisher Site | Google Scholar
J. Castex, D. Willmann, T. Kanouni et al., “Inactivation of Lsd1 triggers senescence in trophoblast stem cells by induction of Sirt4,” Cell Death & Disease, vol. 8, no. 2, article e2631, 2017.
View at: Publisher Site | Google Scholar
L. Du, X. Liu, Y. Ren et al., “Loss of SIRT4 promotes the self-renewal of breast cancer stem cells,” Theranostics, vol. 10, no. 21, pp. 9458–9476, 2020.
View at: Publisher Site | Google Scholar
S. Kumar and D. B. Lombard, “Functions of the sirtuin deacylase SIRT5 in normal physiology and pathobiology,” Critical Reviews in Biochemistry and Molecular Biology, vol. 53, no. 3, pp. 311–334, 2018.
View at: Publisher Site | Google Scholar
C. Schlicker, M. Gertz, P. Papatheodorou, B. Kachholz, C. F. W. Becker, and C. Steegborn, “Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5,” Journal of Molecular Biology, vol. 382, no. 3, pp. 790–801, 2008.
View at: Publisher Site | Google Scholar
C. Chinopoulos, “The mystery of extramitochondrial proteins lysine succinylation,” International Journal of Molecular Sciences, vol. 22, no. 11, p. 6085, 2021.
View at: Publisher Site | Google Scholar
X. F. Chen, M. X. Tian, R. Q. Sun et al., “SIRT5 inhibits peroxisomalACOX1 to prevent oxidative damage and is downregulated in liver cancer,” EMBO Reports, vol. 19, no. 5, article e45124, 2018.
View at: Publisher Site | Google Scholar
L. Zorro Shahidian, M. Haas, S. Le Gras et al., “Succinylation of H3K122 destabilizes nucleosomes and enhances transcription,” EMBO Reports, vol. 22, no. 3, article e51009, 2021.
View at: Publisher Site | Google Scholar
T. Ou, W. Yang, W. Li et al., “SIRT5 deficiency enhances the proliferative and therapeutic capacities of adipose-derived mesenchymal stem cells via metabolic switching,” Clinical and Translational Medicine, vol. 10, no. 5, article e172, 2020.
View at: Publisher Site | Google Scholar
L. Zhou, F. Wang, R. Sun et al., “SIRT5 promotes IDH2 desuccinylation and G6PD deglutarylation to enhance cellular antioxidant defense,” EMBO Reports, vol. 17, no. 6, pp. 811–822, 2016.
View at: Publisher Site | Google Scholar
Y. Zhang, S. S. Bharathi, M. J. Rardin et al., “SIRT5 binds to cardiolipin,” The Journal of Biological Chemistry, vol. 292, no. 24, pp. 10239–10249, 2017.
View at: Publisher Site | Google Scholar
G. E. Salazar-Noratto, G. Luo, C. Denoeud et al., “Understanding and leveraging cell metabolism to enhance mesenchymal stem cell transplantation survival in tissue engineering and regenerative medicine applications,” Stem Cells, vol. 38, no. 1, pp. 22–33, 2020.
View at: Publisher Site | Google Scholar
G. Liu, H. Chen, H. Liu, W. Zhang, and J. Zhou, “Emerging roles of SIRT6 in human diseases and its modulators,” Medicinal Research Reviews, vol. 41, no. 2, pp. 1089–1137, 2021.
View at: Publisher Site | Google Scholar
H. Wang, D. Diao, Z. Shi et al., “SIRT6 controls hematopoietic stem cell homeostasis through epigenetic regulation of Wnt signaling,” Cell Stem Cell, vol. 18, no. 4, pp. 495–507, 2016.
View at: Publisher Site | Google Scholar
C. M. Ferrer, M. Alders, A. V. Postma et al., “An inactivating mutation in the histone deacetylase SIRT6 causes human perinatal lethality,” Genes & Development, vol. 32, no. 5–6, pp. 373–388, 2018.
View at: Publisher Site | Google Scholar
W. Zhang, H. Wan, G. Feng et al., “SIRT6 deficiency results in developmental retardation in cynomolgus monkeys,” Nature, vol. 560, no. 7720, pp. 661–665, 2018.
View at: Publisher Site | Google Scholar
P. Xu, T. T. Wang, X. Z. Liu et al., “Sirt6 regulates efficiency of mouse somatic reprogramming and maintenance of pluripotency,” Stem Cell Research & Therapy, vol. 10, no. 1, p. 9, 2019.
View at: Publisher Site | Google Scholar
H. Wei, M. B. Khawar, W. Tang, L. Wang, and W. Li, “Sirt6 is required for spermatogenesis in mice,” Aging, vol. 12, no. 17, pp. 17099–17113, 2020.
View at: Publisher Site | Google Scholar
H. Pan, D. Guan, X. Liu et al., “SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2,” Cell Research, vol. 26, no. 2, pp. 190–205, 2016.
View at: Publisher Site | Google Scholar
E. Michishita, J. Y. Park, J. M. Burneskis, J. C. Barrett, and I. Horikawa, “Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins,” Molecular Biology of the Cell, vol. 16, no. 10, pp. 4623–4635, 2005.
View at: Publisher Site | Google Scholar
S. Chen, M. F. Blank, A. Iyer et al., “SIRT7-dependent deacetylation of the U3-55k protein controls pre-rRNA processing,” Nature Communications, vol. 7, no. 1, article 10734, 2016.
View at: Publisher Site | Google Scholar
J. Shin, M. He, Y. Liu et al., “SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease,” Cell Reports, vol. 5, no. 3, pp. 654–665, 2013.
View at: Publisher Site | Google Scholar
S. Paredes, M. Angulo-Ibanez, L. Tasselli et al., “SIRT7 regulates rDNA instability-induced senescence,” The Journal of Biological Chemistry, vol. 293, no. 28, pp. 11242–11250, 2018.
View at: Publisher Site | Google Scholar
J. Liu, Y. J. Zhao, W. H. Li, Y. N. Hou, and H. C. Lee, “Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels,” Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 31, pp. 8283–8288, 2017.
View at: Publisher Site | Google Scholar
S. Bi, Z. Liu, Z. Wu et al., “SIRT7 antagonizes human stem cell aging as a heterochromatin stabilizer,” Protein & Cell, vol. 11, no. 7, pp. 483–504, 2020.
View at: Publisher Site | Google Scholar
G. Li, X. Tang, S. Zhang et al., “SIRT7 activates quiescent hair follicle stem cells to ensure hair growth in mice,” The EMBO Journal, vol. 39, no. 18, article e104365, 2020.
View at: Publisher Site | Google Scholar
E. E. M. Chen, W. Zhang, C. C. Y. Ye et al., “Knockdown of SIRT7 enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells partly via activation of the Wnt/ β-catenin signaling pathway,” Cell Death & Disease, vol. 8, no. 9, article e3042, 2017.
View at: Publisher Site | Google Scholar
Y. Nakamura, M. Ogura, D. Tanaka, and N. Inagaki, “Localization of mouse mitochondrial SIRT proteins: shift of SIRT3 to nucleus by co-expression with SIRT5,” Biochemical and Biophysical Research Communications, vol. 366, no. 1, pp. 174–179, 2008.
View at: Publisher Site | Google Scholar
D. W. Koh, T. M. Dawson, and V. L. Dawson, “Mediation of cell death by poly(ADP-ribose) polymerase-1,” Pharmacological Research, vol. 52, no. 1, pp. 5–14, 2005.
View at: Publisher Site | Google Scholar
L. Zhang, J. Cao, L. Dong, and H. Lin, “TiPARP forms nuclear condensates to degrade HIF-1α and suppress tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 117, no. 24, pp. 13447–13456, 2020.
View at: Publisher Site | Google Scholar
J. Diefenbach and A. Burkle, “Poly-ADP-ribosylation in health and disease,” Cellular and Molecular Life Sciences: CMLS, vol. 62, no. 7–8, pp. 721–730, 2005.
View at: Publisher Site | Google Scholar
P. O. Hassa, S. S. Haenni, M. Elser, and M. O. Hottiger, “Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?” Microbiology and Molecular Biology Reviews, vol. 70, no. 3, pp. 789–829, 2006.
View at: Publisher Site | Google Scholar
J. Groslambert, E. Prokorova, and I. Ahel, “ADP-ribosylation of DNA and RNA,” DNA Repair, vol. 105, article 103144, 2021.
View at: Publisher Site | Google Scholar
M. S. Cohen, “Interplay between compartmentalized NAD⁺ synthesis and consumption: a focus on the PARP family,” Genes & Development, vol. 34, no. 5–6, pp. 254–262, 2020.
View at: Publisher Site | Google Scholar
K. Azarm and S. Smith, “Nuclear PARPs and genome integrity,” Genes & Development, vol. 34, no. 5–6, pp. 285–301, 2020.
View at: Publisher Site | Google Scholar
E. E. Alemasova and O. I. Lavrik, “Poly(ADP-ribosyl) ation by PARP1: reaction mechanism and regulatory proteins,” Nucleic Acids Research, vol. 47, no. 8, pp. 3811–3827, 2019.
View at: Publisher Site | Google Scholar
M. Zeniou, L. Nguekeu-Zebaze, and F. Dantzer, “Therapeutic considerations of PARP in stem cell biology: relevance in cancer and beyond,” Biochemical Pharmacology, vol. 167, pp. 107–115, 2019.
View at: Publisher Site | Google Scholar
B. G. Ju, D. Solum, E. J. Song et al., “Activating the PARP-1 Sensor Component of the Groucho/ TLE1 Corepressor Complex Mediates a CaMKinase IIδ-Dependent Neurogenic Gene Activation Pathway,” Cell, vol. 119, no. 6, pp. 815–829, 2004.
View at: Publisher Site | Google Scholar
A. C. Hau, B. M. Grebbin, Z. Agoston et al., “MEIS homeodomain proteins facilitate PARP1/ARTD1-mediated eviction of histone H1,” The Journal of Cell Biology, vol. 216, no. 9, pp. 2715–2729, 2017.
View at: Publisher Site | Google Scholar
F. Gao, S. W. Kwon, Y. Zhao, and Y. Jin, “PARP1 Poly(ADP-ribosyl)ates Sox2 to Control Sox2 Protein Levels and FGF4 Expression during Embryonic Stem Cell Differentiation,” Journal of Biological Chemistry, vol. 284, no. 33, pp. 22263–22273, 2009.
View at: Publisher Site | Google Scholar
A. Dis, B. Sh, D. Kssc, and B. Sjka, “PARP-1 regulates mouse embryonic neural stem cell proliferation by regulating PDGFRα expression,” Biochemical and Biophysical Research Communications, vol. 526, no. 4, pp. 986–992, 2020.
View at: Publisher Site | Google Scholar
A. Okuda, S. Kurokawa, M. Takehashi et al., “Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells,” BMC Neuroscience, vol. 18, no. 1, p. 14, 2017.
View at: Publisher Site | Google Scholar
M. M. Nelson, J. D. Hoff, M. L. Zeese, and G. Corfas, “Poly (ADP-ribose) polymerase 1 regulates cajal-retzius cell development and neural precursor cell adhesion,” Frontiers in Cell and Developmental Biology, vol. 9, article 693595, 2021.
View at: Publisher Site | Google Scholar
X. Luo, K. W. Ryu, D. S. Kim et al., “PARP-1 Controls the Adipogenic Transcriptional Program by PARylating C/EBPβ and Modulating Its Transcriptional Activity,” Molecular Cell, vol. 65, no. 2, pp. 260–271, 2017.
View at: Publisher Site | Google Scholar
A. R. Chaudhuri and A. Nussenzweig, “The multifaceted roles of PARP1 in DNA repair and chromatin remodelling,” Nature Reviews. Molecular Cell Biology, vol. 18, no. 10, pp. 610–621, 2017.
View at: Publisher Site | Google Scholar
G. Manic, A. A. Sistigu, F. Corradi, M. Musella, R. de Maria, and I. Vitale, “Replication stress response in cancer stem cells as a target for chemotherapy,” Seminars in Cancer Biology, vol. 53, pp. 31–41, 2018.
View at: Publisher Site | Google Scholar
C. C. S. Chini, T. R. Peclat, G. M. Warner, S. Kashyap, and E. N. Chini, “CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD⁺ and NMN levels,” Nature Metabolism, vol. 2, no. 11, pp. 1284–1304, 2020.
View at: Publisher Site | Google Scholar
P. Muñoz, M. Mittelbrunn, H. de la Fuente et al., “Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse,” Blood, vol. 111, no. 7, pp. 3653–3664, 2008.
View at: Google Scholar
N. van de Donk, P. G. Richardson, and F. Malavasi, “CD38 antibodies in multiple myeloma: back to the future,” Blood, vol. 131, no. 1, pp. 13–29, 2018.
View at: Publisher Site | Google Scholar
E. N. Chini, C. C. S. Chini, J. M. Espindola Netto, G. C. de Oliveira, and W. van Schooten, “The pharmacology of CD38/NADase: an emerging target in cancer and diseases of aging,” Trends in Pharmacological Sciences, vol. 39, no. 4, pp. 424–436, 2018.
View at: Publisher Site | Google Scholar
K. W. Bock, “Functions of aryl hydrocarbon receptor (AHR) and CD38 in NAD metabolism and nonalcoholic steatohepatitis (NASH),” Biochemical Pharmacology, vol. 169, article 113620, 2019.
View at: Publisher Site | Google Scholar
J. Camacho-Pereira, M. G. Tarragó, C. C. Chini et al., “CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism,” Cell Metabolism, vol. 23, no. 6, pp. 1127–1139, 2016.
View at: Publisher Site | Google Scholar
Z. L. Piedra-Quintero, Z. Wilson, P. Nava, and M. Guerau-de-Arellano, “CD38: An immunomodulatory molecule in inflammation and autoimmunity,” Frontiers in Immunology, vol. 11, article 597959, 2020.
View at: Publisher Site | Google Scholar
B. Hao, S. E. Webb, A. L. Miller, and J. Yue, “The role of Ca²⁺ signaling on the self-renewal and neural differentiation of embryonic stem cells (ESCs),” Cell Calcium, vol. 59, no. 2–3, pp. 67–74, 2016.
View at: Publisher Site | Google Scholar
W. Wei, H. Sun, K. Ting et al., “Inhibition of Cardiomyocytes differentiation of mouse embryonic stem cells by CD38/cADPR/Ca²⁺ signaling pathway,” Journal of Biological Chemistry, vol. 287, no. 42, pp. 35599–35611, 2012.
View at: Publisher Site | Google Scholar
C. Sun, K. Wang, A. J. Stock et al., “Re-equilibration of imbalanced NAD metabolism ameliorates the impact of telomere dysfunction,” The EMBO Journal, vol. 39, no. 21, article e103420, 2020.
View at: Publisher Site | Google Scholar
H. Higashida, M. Liang, T. Yoshihara et al., “An immunohistochemical, enzymatic, and behavioral study of CD157/BST-1 as a neuroregulator,” BMC Neuroscience, vol. 18, no. 1, p. 35, 2017.
View at: Publisher Site | Google Scholar
J. Li, H. Li, S. Cai, S. Bai, H. Cai, and X. Zhang, “CD157 in bone marrow mesenchymal stem cells mediates mitochondrial production and transfer to improve neuronal apoptosis and functional recovery after spinal cord injury,” Stem Cell Research & Therapy, vol. 12, no. 1, p. 289, 2021.
View at: Publisher Site | Google Scholar
T. Wakabayashi, H. Naito, T. Iba, K. Nishida, and N. Takakura, “Identification of CD157-positive vascular endothelial stem cells in mouse retinal and choroidal vessels: fluorescence-activated cell sorting analysis,” Investigative Ophthalmology & Visual Science, vol. 63, no. 4, p. 5, 2022.
View at: Publisher Site | Google Scholar
H. Naito, T. Wakabayashi, M. Ishida et al., “Isolation of tissue-resident vascular endothelial stem cells from mouse liver,” Nature Protocols, vol. 15, no. 3, pp. 1066–1081, 2020.
View at: Publisher Site | Google Scholar
T. Wakabayashi, H. Naito, J. I. Suehiro et al., “CD157 marks tissue-resident endothelial stem cells with homeostatic and regenerative properties,” Cell Stem Cell, vol. 22, no. 3, pp. 384–397.e6, 2018.
View at: Publisher Site | Google Scholar
D. W. Summers, D. A. Gibson, A. Diantonio, and J. Milbrandt, “SARM1-specific motifs in the TIR domain enable NAD(+) loss and regulate injury-induced SARM1 activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 41, pp. E6271–E6280, 2016.
View at: Publisher Site | Google Scholar
C. Doran, R. Sugisawa, M. Carty et al., “CRISPR/Cas9-mediated SARM1 knockout and epitope-tagged mice reveal that SARM1 does not regulate nuclear transcription, but is expressed in macrophages,” The Journal of Biological Chemistry, vol. 297, no. 6, article 101417, 2021.
View at: Publisher Site | Google Scholar
M. Carty, J. Kearney, K. A. Shanahan et al., “Cell survival and cytokine release after inflammasome activation is regulated by the Toll-IL-1R protein SARM,” Immunity, vol. 50, no. 6, pp. 1412–1424.e6, 2019.
View at: Publisher Site | Google Scholar
K. Essuman, D. W. Summers, Y. Sasaki, X. Mao, A. DiAntonio, and J. Milbrandt, “The SARM1 Toll/interleukin-1 receptor domain possesses intrinsic NAD⁺ cleavage activity that promotes pathological axonal degeneration,” Neuron, vol. 93, no. 6, pp. 1334–1343.e5, 2017.
View at: Publisher Site | Google Scholar
Y. H. Chen, Y. Sasaki, A. DiAntonio, and J. Milbrandt, “SARM1 is required in human derived sensory neurons for injury-induced and neurotoxic axon degeneration,” Experimental Neurology, vol. 339, article 113636, 2021.
View at: Publisher Site | Google Scholar
Q. Lu, B. O. A. Botchway, Y. Zhang, T. Jin, and X. Liu, “SARM1 can be a potential therapeutic target for spinal cord injury,” Cellular and molecular life sciences : CMLS, vol. 79, no. 3, p. 161, 2022.
View at: Publisher Site | Google Scholar
Y. Sasaki, J. Zhu, Y. Shi et al., “Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection,” Experimental Neurology, vol. 345, article 113842, 2021.
View at: Publisher Site | Google Scholar
T. Bosanac, R. O. Hughes, T. Engber et al., “Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy,” Brain, vol. 144, no. 10, pp. 3226–3238, 2021.
View at: Publisher Site | Google Scholar
A. S. Tibbetts and D. R. Appling, “Compartmentalization of mammalian folate-mediated one-carbon metabolism,” Annual Review of Nutrition, vol. 30, no. 1, pp. 57–81, 2010.
View at: Publisher Site | Google Scholar
L. Yue, Y. Pei, L. Zhong et al., “Mthfd2 modulates mitochondrial function and DNA repair to maintain the pluripotency of mouse stem cells,” Stem Cell Reports, vol. 15, no. 2, pp. 529–545, 2020.
View at: Google Scholar
G. Hoxhaj, I. Ben-Sahra, S. E. Lockwood et al., “Direct stimulation of NADP⁺ synthesis through Akt-mediated phosphorylation of NAD kinase,” Science, vol. 363, no. 6431, pp. 1088–1092, 2019.
View at: Publisher Site | Google Scholar
W. Xu, L. Li, and L. Zhang, “NAD⁺ metabolism as an emerging therapeutic target for cardiovascular diseases associated with sudden cardiac death,” Frontiers in Physiology, vol. 11, p. 901, 2020.
View at: Publisher Site | Google Scholar
L. Guarente, “Cell metabolism. The resurgence of NAD⁺,” Science, vol. 352, no. 6292, pp. 1396-1397, 2016.
View at: Publisher Site | Google Scholar
M. G. Tarragó, C. C. S. Chini, K. S. Kanamori et al., “A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD⁺ decline,” Cell Metabolism, vol. 27, no. 5, pp. 1081–1095.e10, 2018.
View at: Publisher Site | Google Scholar
S. Zha, Z. Li, Q. Cao, F. Wang, and F. Liu, “PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD⁺ levels and increasing SIRT1 activity,” Stem Cell Research & Therapy, vol. 9, no. 1, p. 224, 2018.
View at: Publisher Site | Google Scholar
A. Lucena-Cacace, D. Otero-Albiol, M. P. Jiménez-García, S. Muñoz-Galvan, and A. Carnero, “NAMPT is a potent oncogene in colon cancer progression that modulates cancer stem cell properties and resistance to therapy through Sirt1 and PARP,” Clinical Cancer Research : an official Journal of the American Association for Cancer Research, vol. 24, no. 5, pp. 1202–1215, 2018.
View at: Publisher Site | Google Scholar
M. Igarashi, M. Miura, E. Williams et al., “NAD+ supplementation rejuvenates aged gut adult stem cells,” Aging Cell, vol. 18, no. 3, article e12935, 2019.
View at: Publisher Site | Google Scholar
D. C. Schöndorf, D. Ivanyuk, P. Baden et al., “The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease,” Cell Reports, vol. 23, no. 10, pp. 2976–2988, 2018.
View at: Publisher Site | Google Scholar
X. Sun, B. Cao, M. Naval-Sanchez et al., “Nicotinamide riboside attenuates age-associated metabolic and functional changes in hematopoietic stem cells,” Nature Communications, vol. 12, no. 1, p. 2665, 2021.
View at: Publisher Site | Google Scholar
Y. Zhang, J. Xu, Z. Ren et al., “Nicotinamide promotes pancreatic differentiation through the dual inhibition of CK1 and ROCK kinases in human embryonic stem cells,” Stem Cell Research & Therapy, vol. 12, no. 1, p. 362, 2021.
View at: Publisher Site | Google Scholar
J. Song, J. Li, F. Yang et al., “Nicotinamide mononucleotide promotes osteogenesis and reduces adipogenesis by regulating mesenchymal stromal cells via the SIRT1 pathway in aged bone marrow,” Cell Death & Disease, vol. 10, no. 5, p. 336, 2019.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Xiuna Ji et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

544

Downloads

490

Citations